Episode Details
Back to Episodes
STAAR Surgical Crushes Q1 2026, Returns to Profitability
Description
STAAR Surgicals Q1 2026 results are impressive, with net sales surging by 119.6% to $93.5 million, driven by strong demand in China and the US. China led the way with $47.4 million, thanks to EVO ICL and the new EVO+ launch. The US also had its best quarter ever, with sales over $6 million. Despite macro headwinds, ex-China sales grew 6%, and the US saw a 22% YoY increase. STAAR has now sold over 4 million ICLs globally. The company returned to profitability with a 73.6% gross margin, lower operating expenses, and a net income of $5.2 million. STAAR has $163.9 million in cash and no debt. The company is ramping up Swiss manufacturing and has a smooth Oracle ERP rollout. While no full-year guidance is given, STAAR is well-positioned for growth in lens-based refractive surgery amid myopia trends worldwide.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/8a4cb522b603ed4a